Posted by Michael Wonder on 19 Jan 2026
Organon announces US FDA approval of supplemental new drug application extending duration of use of Nexplanon (etonogestrel implant) 68 mg radiopaque
16 January 2026 - Organon announced today that the US FDA has approved a supplemental new drug application for Nexplanon (etonogestrel implant), which is indicated for use by women of reproductive potential to prevent pregnancy.
The supplemental new drug application extends the duration of use of Nexplanon for up to five years, an extension of the previous three year indication.
